scholarly journals Human papillomavirus infection and disease in men: Impact of HIV

2013 ◽  
Vol 14 (4) ◽  
pp. 183-188 ◽  
Author(s):  
Sinead Delany-Moretlwe ◽  
A Chikandiwa ◽  
J Gibbs
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Sub Saharan Africa ◽  
Anogenital Warts ◽  
African Countries ◽  
Hpv Prevalence ◽  
Papillomavirus Infection ◽  
Significant Burden ◽  
Sub Saharan

There is growing evidence of a significant burden of human papillomavirus (HPV) infection and associated disease in men. High rates of HPV infection have been observed in men from sub-Saharan Africa where HIV prevalence is high. HIV infection increases HPV prevalence, incidence and persistence and is strongly associated with the development of anogenital warts and anal, penile and head and neck cancers in men. Despite increasing access to antiretroviral therapy, there appears to be little benefit in preventing the development of these cancers in HIV-positive men, making prevention of infection a priority. New prevention options that are being introduced in many African countries include male circumcision and HPV vaccination. However, more data are needed on the burden of HPV disease in men before boys are included in HPV vaccination programmes.

scholarly journals Stakeholders’ Understandings of Human Papillomavirus (HPV) Vaccination in Sub-Saharan Africa: A Rapid Qualitative Systematic Review

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 496
Author(s):  
Caroline Deignan ◽  
Alison Swartz ◽  
Sara Cooper ◽  
Christopher J. Colvin
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Sub Saharan Africa ◽  
African Countries ◽  
Qualitative Systematic Review ◽  
Sub Saharan ◽  
And Gender

Cervical cancer rates in Sub-Saharan Africa (SSA) are amongst the highest worldwide. All three of the Human Papillomavirus (HPV) vaccines (9-valent, quadrivalent and bivalent HPV vaccine) provide primary protection against the most common cancer-causing strains of HPV (types 16 and 18) that are known to cause 70% of cervical cancers. Over the last five years, there has been an increase in Sub-Saharan African countries that have introduced the HPV vaccine. The majority of research has been conducted on supply-side barriers and facilitators to HPV vaccination uptake in SSA, yet little research has been conducted on demand-side or end-user perspectives of, and decisions around, HPV vaccination. In order to complement existing research, and inform current and future HPV vaccination implementation approaches, this qualitative systematic review explored Stakeholders’ understandings of HPV vaccination in SSA. This review searched the following databases: Embase (via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, Academic Search Premier, Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, SocINDEX, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL) and found a total of 259 articles. Thirty-one studies were found eligible for inclusion and were analyzed thematically using Braun and Clarke’s methods for conducting a thematic analysis. The quality of included studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist. Three major themes emerged from this analysis; knowledge of HPV vaccination and cervical cancer is intertwined with misinformation; fear has shaped contradictory perceptions about HPV vaccination and gender dynamics are relevant in how stakeholders understand HPV vaccination in SSA.

Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis

2018 ◽  
Vol 94 (6) ◽  
pp. 434-442 ◽  
Author(s):  
Xiaomeng Ma ◽  
Qian Wang ◽  
Jason J Ong ◽  
Christopher K Fairley ◽  
Shu Su ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Meta Analysis ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Central China ◽  
Hiv Positive ◽  
Heterosexual Men ◽  
Hpv Prevalence

ObjectiveHuman papillomavirus (HPV) infection causes multiple cancers in both women and men. In China, both HPV vaccination and cervical cancer screening coverages are low. We aim to investigate the temporal and geographical trends of HPV DNA prevalence in heterosexual men, women, men who have sex with men (MSM) and people living with HIV (PLHIV) in China.MethodsWe conducted a systematic review, collecting publications in PubMed, Web of Science, China National Knowledge Infrastructure (CNKI) and Wanfang Data from January 2000 to May 2017. A total of 247 studies were selected for this meta-analysis to estimate pooled HPV prevalence, incidence of cervical cancer and risk of infection for subgroups. Meta-regression was applied to identify contributing factors to prevalence heterogeneities.ResultsThe national HPV prevalence was 15.6% (95% CI (14.4% to 16.9%)) in women with normal cervical cytology, and Central China had the highest prevalence (20.5% (15.2% to 25.8%)). HPV prevalence in heterosexual men (14.5% (11.3% to 17.7%)) was comparable with that of women (OR=1.09 (0.98 to 1.17)), but HPV prevalence in MSM (59.9% (52.2% to 67.6%)) was significantly higher than that in heterosexual men (OR=8.81 (8.01 to 9.69)). HIV-positive women (45.0% (38.4% to 51.6%)) and HIV-positive MSM (87.5% (82.3% to 90.9%)) had 4.67 (3.61 to 6.03) and 6.46 (5.20 to 8.02) times higher risk of HPV infection than their HIV negative counterparts.ConclusionHPV infection is prevalent in China, particularly in Central China, in comparison with the global level and neighbouring countries. Targeted HPV vaccination for women, MSM and PLHIV and scale-up of cervical screening for women are priorities in curbing the HPV epidemic in China.

scholarly journals Challenges of Human Papillomavirus Infection and Associated Diseases in Low-Resource Countries

2018 ◽  
Vol 142 (6) ◽  
pp. 696-699 ◽  
Author(s):  
Michael Chukwugoziem Nweke ◽  
Clement Abu Okolo ◽  
Yara Daous ◽  
Olukemi Ayotunde Esan
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Developed Countries ◽  
Hpv Infection ◽  
Sub Saharan Africa ◽  
Morbidity And Mortality ◽  
Infection Prevalence ◽  
Screening Programs ◽  
Low Resource ◽  
Sub Saharan

Context.— The prevalence of human papillomavirus (HPV) infection varies worldwide. The high-risk viruses are usually associated with cancers of the cervix, vagina, and vulva in women, cancer of the penis in men, and cancers of the anus, tonsils, oropharynx, and base of the tongue in both sexes. Objectives.— To review literature about the challenges and burden associated with HPV infection in low-resource (ie, developing) countries, focusing on sub-Saharan Africa. To review the prevention, incidence, prevalence, morbidity, and mortality of HPV infections in sub-Saharan Africa. To review the therapy and management of HPV infections in low-resource countries in comparison to developed countries. Data Sources.— Peer-reviewed literature and experience of some of the authors. Conclusions.— Sub-Saharan Africa has high HPV infection prevalence rates, with predominance of high-risk subtypes 16, 18, and 45. The difficulty of access to health care has led to higher morbidity and mortality related to HPV-related cancers. Improvement in screening programs will help in monitoring the spread of HPV infections. Survival studies can be more informative if reliable cancer registries are improved. HPV vaccination is not yet widely available and this may be the key to curtailing the spread of HPV infections in resource-poor countries.

scholarly journals Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 425
Author(s):  
Masayuki Sekine ◽  
Manako Yamaguchi ◽  
Risa Kudo ◽  
Sharon J. B. Hanley ◽  
Megumi Hara ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Pap Test ◽  
Hpv Infection ◽  
Infection Rates ◽  
Human Papillomavirus Vaccination ◽  
Papillomavirus Infection ◽  
Vaccination Recommendation ◽  
Epidemiologic Profile ◽  
The Government

Organized human papillomavirus vaccination (OHPV) in Japan was introduced in 2010 for girls aged 12–16 years who were born in 1994 or later. The rate of OHPV coverage was 70–80%. However, after suspension of the government vaccination recommendation, the coverage dramatically decreased. We aim to investigate the change in prevalence of HPV infection after the initiation of HPV vaccination. We recruited females aged 20–21 years attending public cervical cancer screening from 2014 to 2017 fiscal years (April 2014 to March 2018). Residual Pap test specimens were collected for HPV testing. We compared the prevalence of HPV type-specific infection between women registered in 2014 (born in 1993–1994, including the pre-OHPV generation) and registered in 2015–2017 (born in 1994–1997, the OHPV generation). We collected 2379 specimens. The vaccination coverage figures were 30.7%, 86.6%, 88.4% and 93.7% (p < 0.01) from 2014 to 2017, respectively. The prevalence of HPV16/18 infection significantly decreased from 1.3% in 2014 to 0% in 2017 (p = 0.02). The three most prevalent types were HPV52, 16 and 56 in 2014, and HPV52, 58 and 56 in 2015–2017, respectively. HPV16 and 33 infection rates decreased. On the other hand, the HPV58 infection rate was obviously increased after OHPV from 0.3% to 2.1%. Our study demonstrates that the prevalence of HPV16/18 infection dramatically decreased and the profile of type-specific HPV infection was changed after OHPV.

Human Papillomavirus Infection and Prevention In The Adolescent

2020 ◽  
Author(s):  
Alexandria Richards ◽  
Joanna Stacey
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Transmitted Disease ◽  
Cervical Dysplasia ◽  
Vaccine Safety ◽  
Genital Warts ◽  
Hpv Infection ◽  
Sexually Transmitted ◽  
Papillomavirus Infection

Human papillomavirus, or HPV, is a common sexually transmitted disease, most often acquired during the adolescence or the early 20s. It can be divided into oncogenic and nononcogenic serotypes. It is responsible for genital warts as well as pathologic diseases that can lead to genital cancers and cancers of the oropharyngeal tract in both males and females. The majority of adolescents who acquire HPV infections do not go on to develop cancer. New discoveries about the virus’ persistence and latency direct how we treat adolescents with HPV infections. Recommendations for prevention of HPV include use of the 9-valent vaccine against the most common oncogenic HPV serotypes. Screening should be delayed until the age of 21, with the exception of immunocompromised women. The HPV vaccination is safe and effective, and does not encourage sexual activity among adolescents. Both boys and girls should be vaccinated against HPV at 11 to 12 years of age but may receive the vaccination as early as 9 or as late as 21 (males) or 26 (females) years of age. The vaccine may now also be given in only two doses if the series was started before the age of 15. Follow-up studies in the years after the vaccine’s introduction have shown large decreases in HPV infection rates. This review contains 7 figures, 7 tables and 63 references Key Words: Oncogenic subtype, Oropharyngeal cancer, Infection persistence, Immune tolerance, Cervical dysplasia, Genital warts, 9-valent vaccine, Vaccine safety  

scholarly journals Anal human papillomavirus infection and its relationship with abnormal anal cytology among MSM with or without HIV infection in Japan

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Daisuke Shiojiri ◽  
Daisuke Mizushima ◽  
Misao Takano ◽  
Koji Watanabe ◽  
Naokatsu Ando ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hiv Infection ◽  
Hpv Vaccination ◽  
Epidemiological Data ◽  
Hpv Infection ◽  
Exclusion Criterion ◽  
Abnormal Cytology ◽  
Papillomavirus Infection ◽  
Hpv Genotypes ◽  
History Of

AbstractAnal high-risk human papillomavirus (hr-HPV) infection is widely considered a cause of anal cancer. However, epidemiological data are quite limited in Japan. This study investigated anal HPV infections and cytological abnormalities among MSM with or without HIV infection. Anal swabs were obtained, and cytological results were examined. Hybrid capture-based methodology was used for hr-HPV genotyping. The exclusion criterion was a history of vaccination against HPV. 644 subjects participated, and the overall prevalence of hr-HPV was 59.7% (95% CI 54.7–62.3), HIV-infected had higher prevalence than HIV-uninfected (68.9% vs 40.6%) p < .001. Among hr-HPV-infected participants, 82.8% (312/377) were infected with at least one of 9 valent vaccine-covered hr-HPV genotypes. From regression analysis, detection of abnormal cytology correlated positively with HIV infection (OR 2.17 [95% CI 1.51–3.13]), number of hr-HPV genotypes infected (OR 1.83 [1.59–2.10]), history of STI (OR 1.58 [1.14–2.22]) and No. of lifetime sexual partners (OR 1.56 [1.10–2.21]), albeit multivariate analysis identified the number of detected hr-HPV genotypes (adjusted OR 1.78 [1.54–2.06]) as the independent risk factor for abnormal cytology. High rates of anal hr-HPV infection, especially 9-valent HPV vaccine-preventable hr-HPV were detected among our MSM participants in Japan. HPV vaccination should also be encouraged for MSM in Japan.

scholarly journals Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0244242
Author(s):  
Richard Muwonge ◽  
Partha Basu ◽  
Tarik Gheit ◽  
Devasena Anantharaman ◽  
Yogesh Verma ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Sample Collection ◽  
Community Based ◽  
Hpv 16 ◽  
Indian Women ◽  
Cervical Sample ◽  
Hpv Prevalence ◽  
Hpv Types

In context of the ongoing multi-centric HPV vaccine study in India, unvaccinated married women (N = 1484) aged 18–23 years were recruited in 2012–2015 as age-matched controls to the vaccinated women and followed up yearly. We assess type-specific prevalence, natural history and potential determinants of human papillomavirus (HPV) infection in these unvaccinated women. Cervical samples were collected yearly for at least four consecutive years. A Multiplex Type-Specific E7-Based polymerase chain reaction assay was used to detect 21 HPV types. HPV prevalence was 36.4% during 6 years. Most common HPV types were 16 (6.5%) and 31 (6.1%). Highest persistence were observed for HPV 35 (62.5%) and 52 (25%). New HPV acquisition rate was 5.6/1000 person-months of observation (PMO), highest for HPV 16 (1.1/1000 PMO). Type-specific clearance rates ranged between 2.9–5.5/100 PMO. HPV 16 and/or 18 infections were 41% (95% CI 4–63%) lower among women with 2-<3 years between marriage and first cervical sample collection compared to those with <2 years. HPV prevalence and acquisition rates in young Indian women were lower than their Western counterparts. HPV 16 infections being most common shows the importance and potential impact of HPV vaccination in India. Women with 2–3 years exposure had reduced risk possibly due to higher infections clearance.

Anal and oral human papillomavirus infection in men who have sex with men: implications for risk-targeted vaccination

2020 ◽  
Vol 15 (18) ◽  
pp. 1713-1722
Author(s):  
Maria Gabriella Donà ◽  
Francesca Rollo ◽  
Alessandra Latini ◽  
Maria Benevolo ◽  
Barbara Pichi ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Linear Array ◽  
Hpv Vaccination ◽  
Risk Groups ◽  
Sexually Active ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Papillomavirus Infection ◽  
Significant Burden ◽  
Sex With Men

Aim: Men who have sex with men (MSM) harbor a significant burden of human papillomavirus (HPV)-related diseases that could be prevented by vaccination. Materials & methods: Prevalence of HPVs targeted by the quadrivalent (4vHPV) and nonavalent vaccines (9vHPV) was assessed in anal (n = 443) and oral (n = 193) specimens of immunocompetent, sexually active MSM, using the Linear Array. Results: Of the anal samples, 34.1 and 46.0% were positive for at least one genotype of those covered by the 4vHPV and 9vHPV, respectively. At least one of the HPVs targeted by the 9vHPV was detected in 5.7% of the oral specimens. Conclusion: The majority of the subjects were not currently infected by HPV-16 and other vaccine-preventable HPVs. Universal HPV vaccination should be strongly promoted in order to achieve protection for all risk groups. In the meanwhile, vaccination should be offered to sexually active adult MSM attendees of sexually transmitted infection centers, although its potential benefit for these subjects needs to be further investigated.

The prevalence and risk of human papillomavirus infection in pregnant women

2014 ◽  
Vol 142 (8) ◽  
pp. 1567-1578 ◽  
Author(s):  
P. LIU ◽  
L. XU ◽  
Y. SUN ◽  
Z. WANG
Keyword(s):  
Human Papillomavirus ◽  
Pregnant Women ◽  
Observational Studies ◽  
Meta Analysis ◽  
Hpv Infection ◽  
Study Region ◽  
Hpv Prevalence ◽  
Papillomavirus Infection ◽  
Increased Risk ◽  
Summary Odds Ratio

SUMMARYA series of observational studies were evaluated concerning the risk of human papillomavirus (HPV) infection in pregnancy; however, the results were controversial. We systematically reviewed and collected data on studies regarding HPV prevalence published up to 30 April 2013, in which HPV was detected in pregnant women or both in pregnant and non-pregnant women. In total, 28 eligible studies were included that provided data on HPV infection concerning 13 640 pregnant women. The overall HPV prevalence in pregnant and age-matched non-pregnant women was 16·82% [95% confidence interval (CI) 16·21–17·47] and 12·25% (95% CI 11·50–13·01), respectively. The prevalence in the in three trimesters was 18·20%, 14·38%, and 19·32%, respectively. HPV-16 was the most frequently observed type, with a prevalence of 3·86% (95% CI 3·40–4·32). The overall HPV prevalence varied by study region, age, and HPV type. The meta-analysis showed a significantly increased risk of HPV infection in pregnant women, with a summary odds ratio (OR) of 1·42 (95% CI 1·25–1·61), especially for those aged <25 years (OR 1·79, 95% CI 1·22–2·63). The results suggest that pregnant women, especially those aged <25 years, are more susceptible to HPV infection.

Sign in / Sign up

Export Citation Format

Share Document